Rapid molecular detection of tuberculosis and rifampicin drug resistance: Retrospective analysis of a national UK molecular service over the last decade

Thorax

Volumn 67, Issue 4, 2012, Pages 361-367

  Seoudi, N ^a,b   Mitchell, S L ^a,c   Brown, T J ^a,c   Dashti, F ^b   Amin, A K ^b   Drobniewski, F A ^a,b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SERVICE; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TUBERCULOSIS; UNITED KINGDOM;

EID: 84858798605     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200610     Document Type: Article

References (23)

1. Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug- resistant-tuberculosis at the beginning of the new millennium. Int J Infect Dis 2002;6(Suppl 1):S21-31. (Pubitemid 40090868)
2. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-44.
3. Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002;57:810-16. (Pubitemid 34984981)
4. Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010;137:393-400.
5. Sam IC, Drobniewski F, More P, et al. Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg Infect Dis 2006;12:752-9. (Pubitemid 43739339)
6. WHO. Policy statement: Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: WHO, 2008.
7. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15.
8. Drobniewski FA. Diagnosing multidrug resistant tuberculosis in Britain. Clinical suspicion should drive rapid diagnosis. BMJ 1998;317:1263-4. (Pubitemid 28502402)
9. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-92. (Pubitemid 351490566)
10. Kirehn TE, Cynamon MH, Inderlied CB, et al. National Committee for Clinical Laboratory Standards. Antimicrobial susceptibility testing for Mycobacterium tuberculosis; tentative standard NCCLS document M24-T. 1994;17:7-11.
11. Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006;44:811-18.
12. Rusch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44:688-92.
13. Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993;12:809-24. (Pubitemid 23162483)
14. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50. (Pubitemid 23083244)
15. De Beenhouwer H, Lhiang Z, Jannes G, et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis 1995;76:425-30.
16. Skenders G, Fry AM, Prokopovica I, et al. Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis 2005;11:1461-3. (Pubitemid 41209148)
17. Drobniewski FA, Caws M, Gibson A, et al. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2003;3:141-7. (Pubitemid 36278123)
18. HPA. Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK Health Protection Agency Centre for Infections. London: HPA, 2009.
19. Sarmiento OL, Weigle KA, Alexander J, et al. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. J Clin Microbiol 2003;41:3233-40. (Pubitemid 36842327)
20. Drobniewski F, Balabanova Y, Coker R. Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med 2004;10:211-17. (Pubitemid 38520765)
21. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010;36:584-93.
22. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006;12:1389-97. (Pubitemid 44455215)
23. Drobniewski FA, Watterson SA, Wilson SM, et al. A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol 2000;49:271-8. (Pubitemid 30132909)